Frontiers in nutrition · 2022
Circulating choline pathway nutrients and risk of moyamoya disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ge Peicong, Zhao Yaobo, Zhai Yuanren, Zhang Qian, Ye Xun, Wang Jia, Wang Rong, Zhang Yan, Zhang Dong, Zhao Jizong
Аннотация
BACKGROUND: Circulating choline pathway nutrients play a critical role in first stroke and recurrent stroke. However, there is limited information available on the effects of choline pathway nutrients on the risk of moyamoya disease (MMD) and its subtypes. We investigated the association between circulating choline and betaine and the incident risk of MMD and its subtypes.
METHODS: The case-control study enrolled 385 patients with MMD [i.e., 110 transient ischemic attack (TIA)-type MMD, 157 infarction-type MMD, and 118 hemorrhagic-type MMD] and 89 matched healthy controls.
RESULTS: Serum choline and betaine were inversely related to the risk of MMD and its subtypes. The risk of MMD was decreased with each increment in choline level [per 1 μmol increase: odds ratio (OR), 0.756; 95% CI, 0.678-0.843] and betaine level (per 1 μmol increase: OR, 0.952; 95% CI, 0.932-0.972), respectively. When choline and betaine were assessed as quartiles, compared with the lowest quartile of serum choline and betaine levels, those in the highest quartile had a significantly decreased risk of MMD (choline, Q4 vs. Q1: OR, 0.023; 95% CI, 0.005-0.118; betaine, Q4 vs. Q1: OR, 0.058; 95% CI, 0.018-0.184).
CONCLUSIONS: Serum choline and betaine were associated with the decreased risk of MMD and its subtypes.
METHODS: The case-control study enrolled 385 patients with MMD [i.e., 110 transient ischemic attack (TIA)-type MMD, 157 infarction-type MMD, and 118 hemorrhagic-type MMD] and 89 matched healthy controls.
RESULTS: Serum choline and betaine were inversely related to the risk of MMD and its subtypes. The risk of MMD was decreased with each increment in choline level [per 1 μmol increase: odds ratio (OR), 0.756; 95% CI, 0.678-0.843] and betaine level (per 1 μmol increase: OR, 0.952; 95% CI, 0.932-0.972), respectively. When choline and betaine were assessed as quartiles, compared with the lowest quartile of serum choline and betaine levels, those in the highest quartile had a significantly decreased risk of MMD (choline, Q4 vs. Q1: OR, 0.023; 95% CI, 0.005-0.118; betaine, Q4 vs. Q1: OR, 0.058; 95% CI, 0.018-0.184).
CONCLUSIONS: Serum choline and betaine were associated with the decreased risk of MMD and its subtypes.